Prothena nets more cash from Novo Nordisk; Khondrion fails to hit endpoint
A year after Novo Nordisk paid $100 million upfront to grab Prothena’s antibody and wider program in ATTR amyloidosis, the deal has hit a milestone, earning more cash for the biotech.
Prothena announced on Tuesday that it has earned a $40 million milestone payment from the Danish pharma. The payment is related to its candidate NNC6019, formerly known as PRX004, a Prothena spokesperson told Endpoints News in an email. The company hit the clinical milestone due to the “initiation of the phase II study,” the spokesperson said. The candidate is meant to treat patients with ATTR cardiomyopathy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.